Payment overview · 2025
General Payments
$2,000.44
107 reported records · 25 companies
Healthcare provider profile · identity verified
Aaron Katzenmeyer
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Acute Care · MADISON, MS · NPI 1538454236
Verified facts
What the public records show
CMS Open Payments records show Aaron Katzenmeyer received $2,000.44 in general payments during 2025 across 107 reported records.
ABBVIE INC. accounted for 11.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $233.95 | 11.7% | 21 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $231.90 | 11.6% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $179.39 | 9.0% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $173.80 | 8.7% | 10 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $163.33 | 8.2% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $139.54 | 7.0% | 10 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $119.22 | 6.0% | 6 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $95.45 | 4.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $88.86 | 4.4% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $81.20 | 4.1% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $76.26 | 3.8% | 4 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $58.44 | 2.9% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $52.03 | 2.6% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $45.24 | 2.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $40.79 | 2.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $39.67 | 2.0% | 2 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $37.77 | 1.9% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $30.59 | 1.5% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.56 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.15 | 1.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.34 | 0.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.85 | 0.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.67 | 0.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.97 | 0.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.47 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,000.44 | 107 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $173.80 | 10 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $163.33 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $140.46 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $135.70 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $134.43 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $134.43 | 9 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $122.92 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $119.22 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $108.98 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $106.61 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $102.39 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $91.80 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $82.22 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $76.26 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $73.56 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $66.51 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $66.51 | 4 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $58.44 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $52.03 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $51.29 | 4 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $45.24 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40.79 | 2 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $37.77 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $30.59 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.67 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $11.27 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $5.11 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $5.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 49 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 142 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 97 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 64 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 123 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
64 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
142 | 28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 512 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 365 | 103 |
| Losartan Potassium | Losartan Potassium | 314 | 76 |
| Omeprazole | Omeprazole | 280 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 274 | 63 |
| Metformin Hcl | Metformin Hcl | 246 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 239 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 224 | 59 |
| Alprazolam | Alprazolam | 219 | 40 |
| Lisinopril | Lisinopril | 200 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 44 |
| Potassium Chloride | Potassium Chloride | 157 | 54 |
| Gabapentin | Gabapentin | 152 | 52 |
| Montelukast Sodium | Montelukast Sodium | 148 | 35 |
| Farxiga | Dapagliflozin Propanediol | 142 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 41 |
| Famotidine | Famotidine | 136 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 131 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 34 |
| Ozempic | Semaglutide | 123 | 21 |
| Allopurinol | Allopurinol | 121 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 114 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 113 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 34 |
| Meloxicam | Meloxicam | 109 | 31 |
| Trazodone Hcl | Trazodone Hcl | 105 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 104 | 76 |
| Furosemide | Furosemide | 103 | 35 |
| Jardiance | Empagliflozin | 97 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 21 |
| Bupropion Xl | Bupropion Hcl | 94 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 82 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 78 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 72 | 12 |
| Carvedilol | Carvedilol | 70 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 15 |
| Buspirone Hcl | Buspirone Hcl | 66 | 12 |
| Mirtazapine | Mirtazapine | 66 | 15 |
| Clonazepam | Clonazepam | 64 | 11 |
| Linzess | Linaclotide | 64 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 60 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 18 |
| Synthroid | Levothyroxine Sodium | 60 | 14 |
| Celecoxib | Celecoxib | 57 | 13 |
| Myrbetriq | Mirabegron | 56 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 56 | 17 |
| Tramadol Hcl | Tramadol Hcl | 56 | 28 |
| Chlorthalidone | Chlorthalidone | 53 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 15 |
| Valacyclovir | Valacyclovir Hcl | 51 | 12 |
| Eliquis | Apixaban | 49 | 12 |
| Nifedipine Er | Nifedipine | 49 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 12 |
| Methylprednisolone | Methylprednisolone | 47 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 18 |
| Promethazine Hcl | Promethazine Hcl | 42 | 13 |
| Atenolol | Atenolol | 41 | 14 |
| Ondansetron Odt | Ondansetron | 41 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Spironolactone | Spironolactone | 38 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | 12 |
| Azithromycin | Azithromycin | 34 | 30 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 33 | suppressed |
| Simvastatin | Simvastatin | 33 | 12 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Naproxen | Naproxen | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Fluconazole | Fluconazole | 29 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | suppressed |
| Prednisone | Prednisone | 28 | 11 |
| Telmisartan | Telmisartan | 28 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Tri-Linyah | Norgestimate-Ethinyl Estradiol | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 19 |
| Estradiol | Estradiol | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Topiramate | Topiramate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 12 |
| Glimepiride | Glimepiride | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Balsalazide Disodium | Balsalazide Disodium | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Larin Fe | Norethindrone-E.Estradiol-Iron | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,000.44 · 107 records | ABBVIE INC. | AIRSUPRA, Auvelity, CAPLYTA, Dyanavel XR, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, INSPIRE, INTELLIS ADAPTIVESTIM, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, Quviviq, REPATHA, REXULTI, Rybelsus, Saxenda, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, Tresiba, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, Veozah, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error